Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2002 Jul-Sep; 44(3): 212–219.
PMCID: PMC2954391



There has been great interest in the neurobiological substrate of the different dimensions of schizophrenia. This has largely focused on structural and functional changes while it has been acknowledged that there is a relation between pharmacological response and neurotransmitter alteration on these dimensions. Atypical anti psychotics which affect both positive and negative symptoms mediate their action predominantly through dopaminergic and serotonergic receptors. The current study extends this further looking at CSF amines. 37 drug naive first episode psychosis patients with the duration of illness less than 2 years were included. Patients were assessed with SAPS (Scale for Assessment of Positive Symptoms) and SANS (Scale for Assessment of Negative Symptoms). Lumbar puncture was done under sterile conditions and CSF was analyzed by HPLC for dopamine, serotonin and their metabolites. Mean CSF 5- HIAA was 25.35ng/dl. Mean CSF 5 HT was 7.72 ng/dl. Mean CSFHVA was 36.99 ng/dl. Mean CSF 5-DA was 3.06 ng/dl. There was significant positive correlation between CSF5-HIAA and Negative and Disorganization dimensions. There was significant negative correlation between CSF HVA and Psychosis dimension. There is evidence to support that the implication of serotonin in Negative and Disorganization dimensions and the Serotonin- Dopamine interaction and dimensions of schizophrenia.

Keywords: Dopamine, Serotonin, Schizophrenia

Full Text

The Full Text of this article is available as a PDF (328K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982 Jul;39(7):784–788. [PubMed]
  • Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry. 1995 May;52(5):341–351. [PubMed]
  • Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK. Symptomatic and neuropsychological components of defect states. Schizophr Bull. 1985;11(3):409–419. [PubMed]
  • Bowers MG, Jr, Rozitis A. Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J Pharm Pharmacol. 1974 Sep;26(9):743–745. [PubMed]
  • Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980 Jan 12;280(6207):66–68. [PMC free article] [PubMed]
  • Csernansky JG, King RJ, Faustman WO, Moses JA, Jr, Poscher ME, Faull KF. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. Br J Psychiatry. 1990 Apr;156:501–507. [PubMed]
  • Kirstein L, Bowers MB, Jr, Heninger G. CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients. Biol Psychiatry. 1976 Aug;11(4):421–434. [PubMed]
  • Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987 Aug;151:145–151. [PubMed]
  • Lindström LH. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Res. 1985 Apr;14(4):265–273. [PubMed]
  • Nielsen JA, Johnston CA. Rapid, concurrent analysis of dopamine, 5-hydroxytryptamine, their precursors and metabolites utilizing high performance liquid chromatography with electrochemical detection: analysis of brain tissue and cerebrospinal fluid. Life Sci. 1982 Dec 20;31(25):2847–2856. [PubMed]
  • Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, Potter WZ. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry. 1990 Jul;47(7):641–648. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications